MediciNova, Inc.
Stock Price Chart
2026/09/29 18:54 UpdatedPrice Trend
2026/09/29 18:54 UpdatedPrice & Trading Details
2026/09/29 18:54 UpdatedPRICE
TRADING
Analyst Recommendations 3 analysts
Updated 2026/09/01Earnings Calendar
Updated 2026/09/01Recent Earnings
| Date | EPS Est. | EPS Actual | Surprise |
|---|---|---|---|
| 2026/08/13 | ¥-10.43 | ¥-7.97 | +23.6% |
| 2026/05/14 | ¥-10.37 | ¥-7.91 | +23.8% |
| 2026/02/20 | ¥-14.53 | ¥-7.75 | +46.7% |
| 2025/11/12 | ¥-18.50 | ¥-9.29 | +49.8% |
Shareholder Composition
Updated 2026/09/01Top Mutual Funds / ETFs
Updated 2026/09/01Major Holders
Updated 2026/09/01| Fund Name | Ownership | Shares | Change |
|---|---|---|---|
|
VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund
|
611.0K | +28.71% | |
|
Fidelity Concord Street Trust-Fidelity Extended Market Index Fund
|
251.7K | -1.36% | |
|
iShares Trust-iShares Micro-Cap ETF
|
159.0K | +28.13% | |
|
Fidelity Concord Street Trust-Fidelity Total Market Index Fund
|
87.6K | 0.00% | |
|
SCHWAB CAPITAL TRUST-Schwab Total Stock Market Index Fund
|
71.5K | 0.00% | |
|
Fidelity Concord Street Trust-Fidelity Series Total Market Index Fund
|
68.4K | 0.00% |
| Institution | Ownership | Shares | Change |
|---|---|---|---|
|
Essex Woodlands Management Inc.
|
1.1M | 0.00% | |
|
Blackrock Inc.
|
752.1K | +6.54% | |
|
Citigroup Inc.
|
635.7K | 0.00% | |
|
Vanguard Capital Management LLC
|
609.1K | -0.33% | |
|
Geode Capital Management, LLC
|
539.3K | -0.83% | |
|
Vanguard Fiduciary Trust Co
|
282.6K | +0.71% |
Financial Performance
2026/09/27 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2023 | 2025 | |
|---|---|---|
| Income Statement | ||
| Revenue | ¥1M | ¥0M |
| Gross Profit | - | ¥0M |
| Operating Income | -¥10M | -¥13M |
| Pretax Income | -¥10M | -¥13M |
| Net Income | -¥9M | -¥12M |
| EPS | -¥0.17 | -¥0.24 |
| Operating Margin | -990.03% | -3,242.47% |
| Balance Sheet | ||
| Total Assets | ¥66M | ¥46M |
| Total Equity | ¥62M | ¥42M |
| Total Liabilities | ¥4M | ¥4M |
| Cash | ¥51M | ¥31M |
| Interest-bearing Debt | ¥0M | ¥0M |
| Equity Ratio | 94.13% | 91.19% |
| D/E Ratio | 0.00 | 0.00 |
| Cash Flow | ||
| Operating CF | -¥7M | -¥10M |
| Investing CF | ¥40M | -¥0M |
| Financing CF | - | ¥0M |
| Free CF | -¥7M | -¥10M |
| Efficiency | ||
| ROE | -13.74% | -28.85% |
| ROA | -12.93% | -26.31% |
Latest IR Information
-
Notice of Change in Major Shareholders
Announcement of a change in major shareholders. Following the filing of Schedule 13D/A, 3D Investment Partners Private Limited's ownership fell below 10%, and it no longer qualifies as a major shareholder. There is no direct impact expected on future performance....
Read more -
Notice Regarding Top-line Results of the Phase 2 Clinical Trial (MN-001-NATG-202) of MN-001 (Taipercast) for Hypertriglyceridemia and Fatty Liver Disease Associated with Type 2 Diabetes
Top-line Phase 2 results of MN-001 (Taipercast) showed a significant reduction in TG, significant increases in HDL-C and HDL-P, and trends toward improvement in liver fat content and body weight. Safety was favorable. Further large-scale trials to evaluate efficacy will...
Read more -
MN-166 (Ibizalast) Phase 2b/3 Clinical Trial in ALS: Final Patient Last Visit Completed for Double‑Blind Treatment Period
In the COMBAT-ALS trial for MN-166 in ALS, the final patient last visit for the double‑blind treatment period has been completed. Top-line data are planned for the end of 2026. No impact on the consolidated results for the year ending...
Read more -
Financial Summary 2026 Fiscal Year 2Q (Interim)
Highlights for the second quarter of the 2026 fiscal year. Operating revenue was 103,732 thousand yen, net income for the period was -787,591 thousand yen. R&D costs were 368,318 thousand yen, SG&A expenses were 549,655 thousand yen. The latest quarter's...
Read more -
Fiscal Year Ending December 2026 Q2 Interim Financial Results Report [U.S. GAAP] (Consolidated)
The consolidated results for the second quarter of the fiscal year ending December 2026 show continued losses. Revenue is 645,423 thousand USD (interim), operating loss is △5,376,995 thousand USD, net loss attributable to parent company shareholders for the interim is...
Read more
Latest News (5 items)
-
Average Analyst Rating: strong_buy
Average Target Price: ¥-
Rating Score: 1.33 (Based on 3 analysts)
※1=Strong Buy, 5=Strong Sell
Company Information
About
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It develops MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent in Phase 2 clinical trial for treating neurological and other disorders, such as progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, and glioblastoma, as well as prevention of acute respiratory distress syndrome. The company is also developing MN-001 (tipelukast), an orally bioavailable small molecule compound in Phase 2 clinical trial to treat fibrotic and other metabolic disorders, including nonalcoholic fatty liver disease and hypertriglycedemia. MediciNova, Inc. was incorporated in 2000 and is headquartered in La Jolla, California.
